title: Ustekinumab in severe complicated erythrodermic psoriasis: rapid clearing, safety, and sustained remission.
abstract: Erythrodermic psoriasis is a severe type of psoriasis associated with comorbidities and high mortality. Patients with erythrodermic psoriasis need hospitalization and systemic treatment. Conventional drugs and biologic agents may not manage to control refractory and complicated erythrodermic psoriasis resulting from treatment failure. Ustekinumab, a human monoclonal antibody against interleukin-12 and 23, seems to be an effective therapeutic option in erythrodermic psoriasis whenever other therapies have failed.
authors.affiliation: 2nd Department of Dermatology and Venereology, Attikon University General Hospital, University of Athens, Medical School, Athens, Greece.
authors.forename: Xanthippe-Argyro
authors.initials: XA
authors.lastname: Koutsoukou
authors.forename: Evangelia
authors.initials: E
authors.lastname: Papadavid
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Theodoropoulos
authors.forename: Dimitris
authors.initials: D
authors.lastname: Rigopoulos
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D003873:Dermatitis, Exfoliative / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D012074:Remission Induction; D012720:Severity of Illness Index; D012867:Skin / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D013997:Time Factors; D016896:Treatment Outcome; D000069549:Ustekinumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D000069549:Ustekinumab
keywords: erythrodermic psoriasis; sepsis; ustekinumab